Technology
Health
Biotechnology

Cytokinetics

$14.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.06 (0.43%) As of 1:55 PM EDT today
+$0.06 (0.43%) Today

Why Robinhood?

You can buy or sell Cytokinetics and other stocks, options, ETFs, and crypto commission-free!

About CYTK

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Read More The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Employees
130
Headquarters
South San Francisco, California
Founded
1997
Market Cap
820.92M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
495.70K
High Today
$14.30
Low Today
$13.93
Open Price
$13.99
Volume
212.75K
52 Week High
$14.30
52 Week Low
$5.75

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
US
North America

CYTK News

ReutersAug 9

Edited Transcript of CYTK earnings conference call or presentation 8-Aug-19 8:30pm GMT

24

CYTK Earnings

-$0.75
-$0.63
-$0.52
-$0.40
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.50 per share
Actual
-$0.56 per share

More CYTK News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.